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Abstract : Purpose : Limited data exist about clinically relevant bleeding events related to antiplatelet therapy 
after percutaneous coronary intervention (PCI) in cancer patients. We investigated the risk factors for clinically 
relevant bleeding events in patients with cancer after PCI with stent implantation. Patients and Methods : Pa-
tients with solid cancer subjected to first PCI were divided into active (n = 45) and non-active cancer groups 
(n = 44). The active group included non-operable patients on treatment or with metastasis ; the non-active in-
cluded those already subjected to or for whom radical surgery was planned within 3 months after the index 
PCI. Results : During a median follow-up of 2.2 years, 11 bleeding events occurred, with only one occurring in 
the non-active cancer group. Half of them occurred during the dual-antiplatelet therapy (DAPT) period, and 
the rest occurred during single-antiplatelet therapy (SAPT) period. Kaplan-Meier analysis showed significantly 
more bleeding events in the active cancer group (p = 0.010). Multivariate Cox regression hazard analysis revealed 
cancer activity as a significant independent risk factor for bleeding (p = 0.023) ; but not for three-point major 
adverse cardiovascular events. Conclusion : Clinically relevant bleeding risk after PCI was significantly lower in 
non-active cancer. Active cancer group had clinically relevant bleeding during both DAPT and SAPT periods. J. 
Med. Invest. 68 : 29-37, February, 2021
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INTRODUCTION
 
Cardiovascular diseases in cancer patients are currently 
attracting attention from both cardiologists and oncologists 
worldwide (1-3). Recent developments in therapy have improved 
the prognosis of patients with cancer. Along with this progress, 
patients with concomitant cancer and cardiovascular diseases 
are increasing. Specifically, coronary artery disease (CAD) often 
coexists with cancer, as some risk factors (e.g., smoking) are com-
mon in both arteriosclerosis and cancer. However, available evi-
dence on CAD treatment in patients with cancer is insufficient. 
Irrespective of type, cancer induces a prothrombotic state, 
potentially leading to cancer-associated thrombosis (4, 5). Fur-
thermore, patients with cancer have higher bleeding risks when 
treated with anti-thrombotic drugs for venous thromboembolism 
(6). An increased risk of bleeding due to anticoagulation therapy 
with direct oral anticoagulants (DOAC) or warfarin has been 
reported (7-11). Percutaneous coronary intervention (PCI) with 
stent implantation, which requires extended treatment with 
dual-antiplatelet therapy (DAPT) followed by single-antiplatelet 
therapy (SAPT), is often performed as treatment for CAD in 
these patients. A few studies have reported that patients with 
cancer experience a higher bleeding rate after PCI (12, 13). 
Nevertheless, the long-term prognostic bleeding risk of DAPT or 
SAPT in these patients has been rarely reported in the past, and 
the actual bleeding risk following PCI procedures is unknown. 
Therefore, we investigated the risk factors for clinically relevant 




The present study was conducted in accordance with the Dec-
laration of Helsinki and ethical standards ; the study protocol 
was approved by the local ethics committee of Osaka Interna-
tional Cancer Institute (approval no. 19046). The requirement 
for acquisition of informed consent was waived owing to the 
retrospective nature of the study.
Patients who were diagnosed with qualifying cancer and who 
received PCI from 2013 to 2018 at Osaka International Cancer 
Institute were enrolled in this study. Patients (1) who had under-
gone either PCI with stent implantation or coronary artery by-
pass grafting before 2013, (2) who died of cancer within 1 month 
and did not have bleeding events, or (3) who had been treated 
with DAPT prior to the index PCI were excluded. Baseline 
clinical data and outcomes were obtained from medical records. 
Patients were followed-up up to 3 years after the index PCI. All 
PCI procedures were performed by experienced interventionists.
Chronic kidney disease was defined as an estimated glomeru-
lar filtration rate of < 60 mL / min / 1.73 m2 for > 3 months. Over-
weight was defined as body mass index > 25 kg / m2. 
Definitions of Primary and Secondary Endpoints
The primary endpoint of the study was bleeding events, which 
were categorized into Bleeding Academic Research Consor-
tium (BARC) types 2, 3, and 5 (14). Bleeding events included 
intracranial bleeding and gastrointestinal or colorectal bleed-
ing requiring endoscopic hemostasis, as well as any bleeding 
requiring blood transfusion, hospitalization, or medical care or 
death caused by bleeding. Only patients with clinically proven 
ischemia underwent PCI with stent implantation. Evidence of 
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cardiac ischemia was determined by fractional flow reserve, 
myocardial scintigraphy, or angiographical stenosis ≥ 90% ac-
cording to the American Heart Association classification. As the 
secondary endpoint, 3-point major adverse cardiovascular events 
(3P-MACEs) were defined as cardiac death, nonfatal myocardial 
infarction (MI), and nonfatal stroke.
Definition of Active Cancer and Non-active Cancer
For individuals with multiple primary cancers, the most re-
cently diagnosed cancer was considered. The cancer’s activity 
status was categorized according to the operability by radical 
surgery. The non-active cancer group included patients who had 
already undergone radical surgery or endoscopic cancer resec-
tion, as well as those who had planned radical surgery within 
3 months after and 5 years before the index PCI. Active cancer 
was determined as cancer currently treated with chemotherapy 
and / or radiation therapy with no indication for radical surgery 
for any reason. One reason for this group categorization was that 
operable patients could have similar characteristics to patients 
without cancer after radical surgery. In addition, we included 
patients who had planned to have radical surgery “within 3 
months” because the current guidelines recommend 3 months of 
DAPT for high bleeding risk patients, such as those with cancer.
Data Analysis
Continuous data are reported as means ± standard deviation, 
and prevalence is expressed as percentage (%). Categorical data 
were compared using the chi-squared test or Fisher’s exact test. 
DAPT duration data were not normally distributed and were 
compared using the Wilcoxon signed-rank test. Event-free sur-
vival (EFS) relative to bleeding, all-cause death, and 3P-MACE 
were assessed using Kaplan-Meier survival analysis, and dif-
ferences between the groups were compared using the log-rank 
test. The risks of developing bleeding events and 3P-MACE were 
estimated by hazard ratio (HR) and their 95% confidence inter-
vals (CI) based on Cox proportional hazards models. Variables 
with P < 0.1 in the univariate analysis were included in a multi-
variate model to identify independent risk factors. For statistical 
analysis, P < 0.05 was considered statistically significant. Due to 
the small sample size, some factors could not be assessed by Cox 
regression hazards models and were indicated as “NA.” All sta-
tistical analyses were performed using JMP version 11.0 (SAS 
Inc., Tokyo, Japan).
RESULTS
Baseline Characteristics of the Study Participants
The data of 236 patients subjected to PCI with stent implan-
tation from 2013 to 2018 were collected. Of these, 84 patients 
without cancer and 50 patients who underwent PCI with stent 
implantation before 2013 were excluded. Patients with malig-
nant lymphoma and leukemia, those who died of cancer within 
1 month after PCI, and those who received DAPT before PCI for 
any reasons were also excluded. Finally, 89 patients were catego-
rized into either the active cancer group (n = 45) or the non-active 
cancer group (n = 44) (Figure 1). Within the non-active cancer 
group, 17 of 44 patients underwent radical surgery at < 3 months 
after the index PCI, 19 underwent radical surgery at < 6 months, 
2 at < 12 months, and 6 at < 5 years before PCI. During the fol-
low-up period, 11 bleeding events, 8 3P-MACEs, and 18 all-cause 
deaths occurred.
The baseline characteristics of all patients and for each group 
are summarized in Table I. The prevalence of acute coronary 
syndrome (ACS) and atrial fibrillation (AF), average left ventric-
ular ejection fraction, and oral anticoagulant use were signifi-
cantly different between groups. The percentage of drug-eluting 
stent (DES) implantation over bare metal stent (BMS) was not 
significantly different between groups. For prognostic assess-
ment, the median follow-up period was 2.2 years [interquartile 
range (IQR) : 0.7–3.0 years] for the primary endpoint and 2.5 
years [IQR : 0.7–3.0] for the secondary endpoint. Kaplan-Meier 
analysis for all-cause death, as the preferred indicator of prog-
nosis for these two groups, is shown in Figure 2. The all-cause 
death rate in 3 years was much higher in the active than in the 
non-active cancer group (log-rank test, P = 0.018), most likely 
due to differences in cancer stages, as indicated by the preva-
lence of metastasis in Table I.
Figure 1.　Study flowchart 
PCI, percutaneous coronary intervention ; DAPT, dual-antiplatelet therapy







(n = 45) P value
Age 71 ± 7.4 72 ± 7.0 71 ± 7.8 0.548 
Male sex 76 (85) 38 (86) 38 (84) 1.000 
ACS 12 (13) 1 (2) 11 (24) 0.004
Drug eluting stent 57 (64) 29 (66) 28 (62) 0.826
Atrial fibrillation 9 (10) 1 (2) 8 (18) 0.030 
Multi-vessel disease 26 (29) 13 (30) 13 (29) 1.000
Number of implanted stents 1.3 ± 0.7 1.3 ± 0.5 1.4 ± 0.1 0.287
Total length of the stent, median (IQR) (s) 28 (20-39) 28 (20-40) 28 (24-40)   0.263*
LAD PCI 56 (63) 28 (64) 28 (62) 1.000 
DAPT duration, median (IQR) (m) 9 (3-12) 10 (3-12) 8 (3-12)   0.558*  
Chronic kidney disease 26 (29) 14 (32) 12 (27) 0.646 
Hypertension 59 (66) 28 (64) 31 (69) 0.658 
Dyslipidemia 50 (56) 25 (57) 25 (56) 1.000 
Diabetes mellitus 39 (44) 17 (39) 22 (49) 0.395 
Current smoking 14 (16) 7 (16) 7 (16) 1.000
Overweight 12 (13) 4 (9) 8 (18) 0.353
History of
   Cerebral infarction 10 (11) 3 (7) 7 (16) 0.315 
   Intracranial bleeding 2 (2) 0 (0) 2 (4) 0.495
   Myocardial infarction 10 (11) 3 (7)  7 (16) 0.315
   Congestive heart failure 9 (10) 3 (7) 6 (13) 0.485
Echocardiography
   LVEF (%) 65 ± 9 66 ± 7.5 63 ± 10.0 0.085 
   LV end diastolic diameter (mm) 46 ± 5 46 ± 4.7 45 ± 5.2 0.873
   LV end systolic diameter (mm) 29 ± 5 29 ± 4.8 30 ± 5.5 0.404 
   Mitral regurgitation ≥ type 3 2 (2) 1 (2) 1 (2) 1.000 
Medication
   Oral anti-coagulant 9 (10) 1 (2) 8 (18) 0.030 
   β-blocker 43 (48) 21 (48) 22 (49) 1.000 
   ACE-I / ARB 28 (31) 11 (25) 17 (38) 0.255 
   Diuretics 5 (6) 1 (2) 4 (9) 0.361 
   Statins 70 (79) 35 (80) 35 (78) 1.000
   Proton-pump inhibitor 6 (7) 5 (11) 1 (2) 0.110
   Cancer type
      Digestive tract 33 (37) 24 (55) 9 (20)
      Urinary organs, prostate 16 (18) 7 (16) 9 (20)
      Head, neck 5 (6) 1 (2) 4 (9)
      Breast 6 (7) 3 (7) 3 (7)
      Liver, bile, pancreas 14 (16) 4 (9) 10 (22)
      Lung, bronchus 13 (15) 3 (7) 10 (22)
      Bone, muscle 2 (2) 2 (5) 0 (0)
Metastasis 23 (24) 0 (0) 23 (53) < 0.001
Data are presented as means ± standard deviation or n (%). P-values are for non-active cancer group vs. active cancer group.
Continuous data were analyzed by two-sided Student t-tests. Categorical data were analyzed by Fisher’s exact test. *Wilcoxon 
signed-rank test.
ACS, acute coronary syndrome ; PCI, percutaneous coronary intervention ; LAD, left anterior descending artery ; DAPT, dual 
anti-platelet therapy ; LVEF, left ventricular ejection fraction ; ACE-I, angiotensin-converting-enzyme inhibitor ; ARB, angio-
tensin II receptor blocker.
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Risk Assessment for Clinically Relevant Bleeding (BARC Types 2, 
3, and 5)
Eleven patients presented with bleeding of BARC types 2, 
3, and 5 after PCI. The characteristics are shown in Tables II 
and III. All patients were males, and the cancer types varied. 
Intracranial bleeding occurred in 2 of 11 patients, whereas 
gastrointestinal bleeding was identified in 8 of 11 patients. 
The antiplatelet therapies used when the events occurred are 
indicated in Table III. Bleeding events were observed not only 
during DAPT but also during SAPT regardless of anticoagu-
lant intake. Among 45 patients with active cancer, 8 received 
DOAC ; of these, 2 (25%) patients experienced bleeding events at 
< 3 years. Furthermore, among the remaining 37 patients with 
active cancer who did not receive DOAC, 5 (14%) experienced 
bleeding events during DAPT and 3 (8%) had bleeding events 
during SAPT (Tables II and III). All 8 patients who had gastro-
intestinal bleeding events received proton pump inhibitors since 
introduction of DAPT.
As the primary endpoints, the EFS and rate of bleeding events 
categorized as BARC types 2, 3, and 5 were assessed. The oc-
currence rates of events during the follow-up period (median, 
2.2 years) were 2% and 22% for the non-active and active cancer 
groups, respectively. As shown in Figure 3a, the bleeding rate 
was lower in the non-active than in the active cancer group 
(log-rank test, P = 0.002). The risk of BARC types 2, 3, and 5 
bleeding in the non-active cancer group was low, with only 1 of 
11 patients in this group experiencing a bleeding event. Among 
them, 5 patients had bleeding events during chemotherapy. How-
ever, only 1 patient had a low platelet count (48,000 / µL), which 
might have been due to the bleeding, whereas the others had a 
platelet count of more than 100,000 / µL (Table II). None of them 
had a diagnosis of disseminated intravascular coagulation when 
they had bleeding events. Case number 4 and 6 in Table II were 
related to endoscopic treatment, which were ulcers following 
endoscopic submucosal dissection (ESD) and endoscopic mucosal 
resection (EMR), while case number 9 was related to the endo-
scopic retrograde biliary drainage (ERBD) procedure. 
Next, we assessed significant clinical prognostic factors 
for bleeding (Table IV). The presence of active cancer (HR, 
Table  II.　Characteristics of the Patients with Bleeding Events



















1 73 M NSCLC III 3 - + 11 659 - + 2.36 Intracranial
2 58 M Pancreas IV 3 - - 8 224 + + 1.62 Intracranial
3 80 M Gastric IV 3 - - 1 13 + + 5.31 Gastric tumor
4 77 M NSCLC II 3 - - 34 414 + + 1.37 Gastric ulcer
5 76 M Pharyngeal I 3 - - 8 112 + + 2.09 Duodenum ulcer
6 68 M Laryngeal III 2 - + 12 576 - + 1.62 Colon ulcer
7 63 M Renal IV 3 + - 19 1189 - + 2.86 Small intestine
8 54 M Gastric IV 3 - - 3 216 - + 4.21 Gastric tumor
9 68 M Pancreas IV 5 - - 3 108 - + 0.43 Biliary tract
10 78 M Pancreas II 3 - - 2 83 - - 2.90 Esophagus
11 81 M NSCLC IV 3 - - 4 72 + + 1.35 Unknown
ACE, acute coronary syndrome ; DAPT, dual-antiplatelet therapy ; NSCLC, non-small cell lung cancer ; OAC, oral anticoagulant ; PCI, 
percutaneous coronary intervention ; ESD, endoscopic submucosal dissection 
Figure 2.　Kaplan-Meier analysis of survival for the active cancer 
(n = 45) and non-active cancer groups (n = 44)
Table  III.　Relationship between OAC, Antiplatelet Therapy, and Event Rates
Non-active cancer (n = 44) Active cancer (n = 45)
OAC (+) (n = 1) OAC (-) (n = 43) OAC (+) (n = 8) OAC (-) (n = 37)
DAPT SAPT DAPT SAPT DAPT SAPT DAPT SAPT
BARC types
2, 3, and 5 0 (0) 0 (0) 0 (0) 1 (2.3) 0 (0) 2 (25.0) 5 (13.5) 3 (8.1)
3P-MACE 0 (0) 0 (0) 2 (4.7) 0 (0) 1 (12.5) 2 (25.0) 3 (8.1) 0 (0)
BARC, Bleeding Academic Research Consortium ; DAPT, dual-antiplatelet therapy ; MACE, major adverse cardiovascular event ; OAC, 
oral anticoagulant ; SAPT, single-antiplatelet therapy
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Figure 3.　Kaplan-Meier analysis of the primary and secondary endpoints after PCI. (A) Survival free from bleeding of BARC types 2, 3, and 5 
was compared between the active cancer group (n = 45) and the non-active cancer group (n = 44). (B) Survival free from 3P-MACE was compared 
between the active cancer group (n = 45) and the non-active cancer group (n = 44). 3P-MACE comprised cardiovascular death, nonfatal death, 
and nonfatal MI. 
PCI, percutaneous coronary intervention ; BARC, Bleeding Academic Research Consortium ; 3P-MACE, 3-point major adverse cardiovascular 
events
ＢＡ
Table  IV.　Cox Regression Hazards Model Analysis for Bleeding Events of BARC Types 2, 3, and 5
Univariate analysis Multivariate analysis
HR [95% CI] P value HR [95% CI] P value
Age 1.00 [0.92–1.08] 0.979
Male sex NA NA NA 
Multi-vessel disease 2.29 [0.66–7.63] 0.185
Number of implanted stents 1.41 [0.53–2.82] 0.440
Total length of the stent(s) 1.01 [0.99–1.03] 0.266
Active cancer 12.81 [2.44–235.57] 0.001 9.03 [1.33–176.69] 0.023 
ACS 0.89 [0.05–4.70] 0.914
Drug-eluting stent 0.69 [0.21–2.40] 0.545
Atrial fibrillation 1.04 [0.06–5.45] 0.969
LAD PCI 1.46 [0.42–6.69] 0.563
DAPT duration (months) 0.99 [0.91–1.04] 0.711
Chronic kidney disease 0.97 [0.21–3.36] 0.966
Hypertension 0.88 [0.27–3.36] 0.840
Dyslipidemia 0.42 [0.11–1.38] 0.154 
Diabetes mellitus 1.18 [0.34–3.94] 0.781
Current smoker 1.84 [0.40–6.37] 0.392
Obesity 0.56 [0.03–2.93] 0.548
Previous cerebral infarction NA NA NA 
Previous myocardial infarction 2.39 [0.36–9.50] 0.314
Congestive heart failure 1.30 [0.07–7.03] 0.810
LVEF (%) 0.96 [0.90–1.04] 0.307
   LV end diastolic diameter (mm) 0.97 [0.85–1.09] 0.572
   LV end systolic diameter (mm) 1.02 [0.89–1.14] 0.796
Mitral regurgitation ≥ grade 3 NA NA NA
Oral anticoagulant 1.87 [0.28–7.25] 0.455
β-blocker 0.54 [0.14–1.80] 0.321
ACE-I / ARB 0.45 [0.07–1.75] 0.269
Diuretics 1.63 [0.09–8.53] 0.664
Statin 0.38 [0.11–1.44] 0.142
Metastasis 5.23 [1.54–18.50] < 0.01 2.02 [0.57–8.00] 0.277
Statistically undetermined values are described as “NA.” No bleeding was observed in women and those who had previous cor-
onary intervention or mitral regurgitation > type 3.
ACE-I, angiotensin-converting enzyme inhibitor ; ACS, acute coronary syndrome ; ARB, angiotensin II receptor blocker ; 
BARC, Bleeding Academic Research Consortium ; DAPT, dual-antiplatelet therapy ; LAD, left anterior descending artery ; 
LVEF, left ventricular ejection fraction ; PCI, percutaneous coronary intervention; HR, hazards ratio ; CI, confidence interval.
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12.81 ; 95% CI, 2.44–235.57 ; P = 0.001) and the prevalence of 
metastasis (HR, 5.23 ; 95% CI, 1.54–18.50 ; P < 0.001) were sig-
nificant prognostic factors in Cox proportional hazards models. 
Other clinical characteristics, such as history of coronary risk 
factors, cardiac function, CAD-related medications, and PCI-re-
lated factors were not significant. Further, DAPT duration and 
stent type (DES or BMS) were not significant prognostic factors 
for bleeding events. Multivariate analysis revealed that only ac-
tive cancer was a significant independent risk factor for bleeding 
events (HR, 9.03 ; 95% CI, 1.33–176.69 ; P = 0.023). 
Risk Assessment for 3P-MACE
We also assessed the 3P-MACE rate as a secondary endpoint 
in the two groups. There were no significant differences in DAPT 
duration, percentage of ACS, and history of previous MI or ce-
rebral infarction between the groups (Table I). The occurrence 
rates of events during the follow-up period (median, 2.5 years) 
were 2% and 6% for the non-active and active cancer group, re-
spectively. Overall, 3P-MACE was present in 9% of the patients, 
and Kaplan-Meier analysis did not show significant differences 
between the two groups (Figure 3b). Additionally, Cox propor-
tional hazards models did not indicate active cancer as a signif-
icant prognostic factor (Table V). ACS, number of stents, total 
length of stents, and left ventricular ejection fraction tended to 
be related to 3P-MACE (P <  0.10). Furthermore, multivariate 
analysis showed that these factors were not significant risk fac-
tors for 3P-MACE.
Table  V.　Cox Regression Hazards Model Analysis for 3P-MACEs
Univariate analysis Multivariate analysis
HR [95% CI] P value HR [95% CI] P value
Age 0.97 [0.89–1.06] 0.456
Male sex NA NA NA
Active cancer 2.40 [0.63–11.42] 0.202
ACS 4.39 [0.92–16.83] 0.062 5.81 [0.87–37.06] 0.068
Drug-eluting stent 0.45 [0.11–1.72] 0.239
Atrial fibrillation 2.71 [0.40–11.25] 0.261
Residual coronary stenosis 2.40 [0.63–9.71] 0.192
Multi-vessel disease 2.13 [0.53–8.08] 0.273
Number of implanted stents 1.98 [0.92–3.63] 0.0754 2.98 [0.23–32.05] 0.386
Total length of the stent(s) 1.02 [0.99–1.04] 0.0830 0.98 [0.92–1.05] 0.629
LAD PCI 1.09 [0.29–5.17] 0.902
DAPT duration (months) 0.93 [0.92–1.02] 0.171
Chronic kidney disease 2.15 [0.53–8.14] 0.265
Hypertension 0.39 [0.10–1.46] 0.157
Dyslipidemia 0.61 [0.15–2.32] 0.467
Diabetes mellitus 1.12 [0.28–4.23] 0.871
Current smoker 1.38 [0.21–5.72] 0.698
Obesity NA NA NA 
Previous cerebral infarction 2.33 [0.35–9.66] 0.332
Previous myocardial infarction 1.38 [0.07–7.74] 0.774
Congestive heart failure 4.26 [0.62–18.37] 0.122
LVEF (%) 0.93 [0.87–1.00] 0.052 0.96 [0.89–1.04] 0.309
Mitral regurgitation ≥ type 3 NA NA NA
Oral anticoagulant 4.32 [0.91–16.40] 0.064
β-blocker 1.27 [0.34–5.14] 0.718
ACE-I / ARB 1.13 [0.24–4.29] 0.863
Diuretics NA NA NA 
Statin 1.97 [0.36–36.62] 0.485
Metastasis 1.22 [0.18–5.17] 0.812
Statistically undetermined values are described as “NA.” No 3P-MACE was observed in those who were obese or took diuretics.
ACE-I, angiotensin-converting enzyme inhibitor ; ACS, acute coronary syndrome ; ARB, angiotensin II receptor blocker ; DAPT, 
dual-antiplatelet therapy ; LAD, left anterior descending artery ; LVEF, left ventricular ejection fraction ; PCI, percutaneous 
coronary intervention ; HR, hazards ratio ; CI, confidence interval.
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DISCUSSION
The key findings of our study are as follows : (i) patients with 
non-active cancer, based on our definition, have significantly 
lower bleeding rates than those with active cancer ; (ii) bleeding 
after PCI may occur during both DAPT and SAPT ; and (iii) 
most bleeding sites involve the gastrointestinal tract.
In our definition of non-active cancer, patients scheduled for 
radical surgery within 3 months were included, in addition to pa-
tients who had already received interventions. In the real-world 
clinical setting, CAD is often diagnosed during preoperative 
examination for cancer surgery ; at this time, cardiologists and 
oncologists make difficult decisions regarding when to perform 
PCI. It was reported that, historically, patients with cancer 
experience fewer in-hospital bleeding events than do current 
patients with prostate, colon, and lung cancer (15). As patients 
with cancer are known to have a higher bleeding risk, a better 
stratification of risk for these patients is needed. As indicated in 
the European Society of Cardiology guidelines (16), the recom-
mended DAPT duration after PCI for stable CAD in patients 
with high bleeding risk is 3 months. Thus, we defined “PCI < 3 
months before planned radical surgery” as non-active cancer for 
further stratification of bleeding risk. Nonetheless, active cancer 
is sometimes difficult to define. However, whether the patients 
are eligible for or have already had radical surgery could be an 
easy and clear indicator of risk stratification. Accordingly, we 
chose the criteria for “active” and “non-active” cancer. 
One of the major differences in the baseline characteristics of 
the two groups was the prevalence of ACS, which was higher in 
the active than in the non-active cancer group. This finding is 
reasonable since ACS should be treated with primary PCI even 
in cases of active cancer ; more patients with non-active cancer 
underwent PCI for stable CAD because of their relatively better 
prognosis.
Impact of Cancer Activity on Bleeding Event Rates After PCI
Several studies have reported bleeding risks after PCI largely 
in patients with ischemic heart disease but without cancer. For 
example, the 1-year outcomes of bleeding of BARC types 2 and 
3 were observed in 3.6% and 1.8% of patients, respectively (17). 
Another study reported the bleeding risk in patients treated 
for 3 months with DAPT (ticagrelor and aspirin), followed by 
randomized assignment to the ticagrelor plus placebo group 
or DAPT continuation group. The risk of BARC type 3 or 5 
bleeding at 1 year was reported to be 1.0% for the placebo group 
and 2.0% for the DAPT group (18). Furthermore, in the AFIRE 
study, the bleeding risk was the safety endpoint of rivaroxaban 
monotherapy or single antiplatelet plus rivaroxaban for patients 
with AF and those who underwent PCI at > 1 year earlier (19). 
The study reported bleeding event rates of 1.62% and 2.76% per 
patient-year for the rivaroxaban monotherapy group and the 
single antiplatelet plus rivaroxaban group, respectively. When 
considering patients with cancer, it is easy to imagine that those 
with advanced cancer have more bleeding events. Nevertheless, 
available evidence for bleeding events after PCI is limited. In one 
of the few studies involving patients with cancer who underwent 
PCI, the prevalence of cancer was an independent determinant 
of the cumulative incidence of hospitalization for bleeding (12). 
Another important study reported the bleeding risks of DAPT 
among 9240 patients with ACS on DAPT with a median fol-
low-up period of 17 months ; 1.8% of the patients had a confirmed 
neoplasm event, and the rate of Global Use of Strategies to Open 
Occluded Coronary Arteries severe / moderate bleeding was 
higher in those with than in those without neoplasms (11.2 vs. 
1.5%) (13). Considering the follow-up period, the bleeding event 
rate of 11.2% was similar to that for our active cancer group 
(22%).
Our results and those of previous studies indicate that pa-
tients with non-active cancer experience lower rates of BARC 
types 2, 3, and 5 bleeding events (2%), which is similar to the 
results of previous studies mostly involving non-cancer patients. 
Conversely, patients with active cancer had a relatively higher 
bleeding rate (22%) than those without a cancer history but had 
a consistent bleeding rate compared to those with neoplasms, as 
reported previously.
In our data, 3 of 10 bleeding events in active cancer patients 
were related to endoscopic treatments, such as ESD, EMR, and 
ERBD. Therefore, the gastrointestinal bleeding events were not 
always due to proton pump inhibitor-resisted ulcers. We should 
recognize that active cancer patients often need these cancer-re-
lated treatments. Moreover, we should be aware of the fact that 
a minor bleeding could progress to a major bleeding when active 
cancer patients on anti-platelet therapy undergo invasive clinical 
procedures. 
Impact of Cancer Activity on 3P-MACE Rates After PCI
As the secondary endpoint, we assessed the 3P-MACE rate in 
the two groups. There was no difference between the active and 
non-active cancer groups according to both Kaplan-Meier and 
Cox regression hazards model analyses. The rates of 3P-MACE 
were 5% and 13% in the non-active and active cancer groups, 
respectively, after a median follow-up period of 2.5 years. Ac-
cording to the AFIRE study (19), the rate of MACE, including 
stroke, MI, unstable angina requiring PCI, and all-cause death, 
was 4.14% per year for the DOAC monotherapy group and 
5.75% per year for the DOAC plus SAPT group. Patients after 
PCI with hypertension had significantly higher 2-year rates of 
MACE (cardiac death, MI, or stent thrombosis) than did pa-
tients without hypertension (7.0% vs. 4.4%) (20). Additionally, 
in the AUGUSTUS study, AF patients who underwent elective 
PCI experienced 5.6% and 5.4% of death and ischemic events 
(stroke, MI, stent thrombosis, and urgent revascularization), 
respectively, when treated with apixaban or vitamin K antag-
onist plus P2Y12 inhibitor over at least a 6-month follow-up 
period (21). The composite endpoint of cardiovascular death, MI, 
and stroke was reported to occur more frequently in patients 
with neoplasms than in those without (18.2% vs. 13.5%) (13). 
Compared to that in previous studies, the 3P-MACE rate in our 
study seemed to be reasonable and was not higher than the rate 
in studies that included mostly non-cancer patients.
Implications for Patients Undergoing PCI
In the real-world clinical setting, it is difficult for cardiologists 
to decide on the timing of PCI and cancer surgery. Furthermore, 
DAPT duration after PCI is controversial. In our study, patients 
with BMS received 1 month of DAPT and those with DES re-
ceived 6 to 12 months of DAPT. As reported in the STOPDAPT-2 
study, a short DAPT duration significantly reduces bleeding 
events after PCI ; thus, DAPT duration has been reduced for 
PCI in non-cancer patients. However, bleeding events during 
SAPT were also detected during the 3-year follow-up period. In 
addition, although bleeding was mostly from the digestive tract, 
the primary cancers also included the lung, renal, larynx, and 
pharynx. 
There are two major risk stratifications of bleeding after PCI, 
the PRECISE DAPT score (22) and the Academic Research Con-
sortium High Bleeding Risk (ARC-HBR) criteria (23). The for-
mer may not provide additional information on cancer patients, 
as the scores and criteria include the white blood cell count, 
hemoglobin, and platelet levels, which are unstable in patients 
undergoing chemotherapy. Although the ARC-HBR criteria 
include the presence of cancer as a bleeding risk factor, further 
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risk stratification of patients with cancer is needed, considering 
accumulated evidence showing that these patients have a higher 
bleeding risk than cancer-naïve patients. However, our study 
may contribute to the improvement of decision-making with re-
spect to indications for PCI in patients with cancer.
LIMITATIONS
This was a retrospective observational study with a relatively 
small sample size ; thus, it was underpowered for the evaluation 
of clinical outcomes such as bleeding or MACEs. As our institute 
does not have an emergency room, and all patients who come to 
our institute have cancer, the number of PCI procedures was 
relatively low. However, all PCI procedures were performed by 
well-trained and certified interventionists. Another limitation 
is that the effects of cancer type, which was different between 
the groups, could not be considered due to the small sample 
size. Furthermore, as the event rate was very low, some factors 
could not be correctly assessed by Cox regression hazards model 
analysis.
CONCLUSIONS
In the present study, we demonstrated that non-active cancer 
patients had a significantly lower rate of bleeding event after 
PCI compared to that in the active cancer group. In addition, the 
rate of 3P-MACE was not different between active and non-ac-
tive groups. 
In summary, our study suggests that post-PCI bleeding in 
patients with non-active cancer may not be a cause for con-
cern ; however, closer attention should be paid on bleeding events 
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